Legal & General Group
ARQT icon

Legal & General Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Legal & General Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.64M Buy
100,808
+15,931
+19% +$371K ﹤0.01% 1856
2026
Q1 		$2M Sell
84,877
-19,136
-18% -$488K ﹤0.01% 1908
2025
Q4 		$3.02M Sell
104,013
-5,431
-5% -$139K ﹤0.01% 1811
2025
Q3 		$2.06M Sell
109,444
-2,159
-2% -$34K ﹤0.01% 1969
2025
Q2 		$1.56M Buy
111,603
+4,025
+4% +$56.4K ﹤0.01% 2063
2025
Q1 		$1.68M Sell
107,578
-249
-0.2% -$3.51K ﹤0.01% 1991
2024
Q4 		$1.5M Sell
107,827
-149
-0.1% -$1.63K ﹤0.01% 2099
2024
Q3 		$1M Buy
107,976
+3,585
+3% +$35.4K ﹤0.01% 2234
2024
Q2 		$971K Buy
104,391
+96,075
+1,155% +$869K ﹤0.01% 2210
2024
Q1 		$82.4K Sell
8,316
-226
-3% -$1.69K ﹤0.01% 2746
2023
Q4 		$27.6K Sell
8,542
-35,221
-80% -$95.7K ﹤0.01% 2913
2023
Q3 		$232K Buy
43,763
+7,579
+21% +$64.5K ﹤0.01% 2688
2023
Q2 		$345K Buy
36,184
+19,148
+112% +$213K ﹤0.01% 2580
2023
Q1 		$187K Buy
17,036
+1,100
+7% +$15.9K ﹤0.01% 2610
2022
Q4 		$236K Buy
15,936
+723
+5% +$12.6K ﹤0.01% 2548
2022
Q3 		$291K Buy
15,213
+3,409
+29% +$77.2K ﹤0.01% 2483
2022
Q2 		$252K Buy
11,804
+3,072
+35% +$63K ﹤0.01% 2553
2022
Q1 		$168K Hold
8,732
– – ﹤0.01% 2728
2021
Q4 		$181K Hold
8,732
– – ﹤0.01% 2762
2021
Q3 		$209K Buy
8,732
+4,949
+131% +$113K ﹤0.01% 2676
2021
Q2 		$103K Sell
3,783
-550
-13% -$15.5K ﹤0.01% 2721
2021
Q1 		$125K Buy
4,333
+1,919
+79% +$59.9K ﹤0.01% 2559
2020
Q4 		$68K Buy
2,414
+257
+12% +$6.29K ﹤0.01% 2704
2020
Q3 		$63K Buy
2,157
+586
+37% +$15.7K ﹤0.01% 2611
2020
Q2 		$48K Sell
1,571
-46
-3% -$1.33K ﹤0.01% 2739
2020
Q1 		$48K Buy
+1,617
New +$43.4K ﹤0.01% 2597

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Legal & General Group's ARQT Position: Q2 2026 in Review

Legal & General Group increased its Arcutis Biotherapeutics (ARQT) stake by 19% in Q2 2026, buying an estimated $371K and bringing the position to 100,808 shares worth $2.64M. The position accounts for ﹤0.01% of the portfolio, ranked #1856.

Legal & General Group first reported a position in ARQT in Q1 2020 and has held it in 26 quarters since. The position peaked at $3.02M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Legal & General Group held 100,808 shares of Arcutis Biotherapeutics worth $2.64M as of Q2 2026.
  • Legal & General Group bought 15,931 Arcutis Biotherapeutics shares in Q2 2026, an estimated $371K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #1856 holding.
  • Legal & General Group first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 26 quarters since.
  • Legal & General Group's Arcutis Biotherapeutics position peaked at $3.02M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.